Amneal Pharmaceuticals, Inc. (AMRX)
| Market Cap | 634.83M |
| Revenue (ttm) | 2.07B |
| Net Income (ttm) | 13.96M |
| Shares Out | 149.37M |
| EPS (ttm) | 0.09 |
| PE Ratio | 46.20 |
| Forward PE | 6.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 960,796 |
| Open | 4.81 |
| Previous Close | 4.62 |
| Day's Range | 4.23 - 4.48 |
| 52-Week Range | 3.90 - 7.45 |
| Beta | 1.25 |
| Analysts | Hold |
| Price Target | 7.17 (+68.7%) |
| Earnings Date | Nov 5, 2021 |
About AMRX
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the d...
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for AMRX stock is "Hold." The 12-month stock price forecast is 7.17, which is an increase of 68.71% from the latest price.
News
Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U...
Amneal to Virtually Participate at Upcoming Investor Conferences
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its investor relations or management team will virtually attend the following investor ...
Amneal Posts Mixed Bag Q3 Earnings; Acquires Puniska To Bolster Injectable Business
Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q3 revenue of $529 million, a marginal increase of 2% Y/Y, missing the consensus of $545.06 million. The increase was driven by Generic product launches a...
Amneal Pharmaceuticals (AMRX) Tops Q3 Earnings Estimates
Amneal (AMRX) delivered earnings and revenue surprises of 5.00% and -3.27%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Amneal Reports Third Quarter 2021 Financial Results
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the third quarter ended September 30, 2021. “Our solid third qua...
Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its inaugural Corporate Responsibility Report with primarily 2020...
Amneal Pharmaceuticals (AMRX) to Report Q3 Results: Wall Street Expects Earnings Growth
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it is launching dexamethasone, 4mg and 6 mg, following Abbreviated New Drug...
Why the Earnings Surprise Streak Could Continue for Amneal (AMRX)
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amneal to Report Third Quarter 2021 Results on November 3, 2021
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2021 financial results on Wednesday, November 3, 2021, prior...
Amneal to Virtually Participate at Morgan Stanley 19th Annual Global Healthcare Conference
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that members of management will participate at the Morgan Stanley Global Healthcare Conferen...
Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study
Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.
Amneal's Parkinson's Candidate Shows Efficacy In Pivotal Trial
Amneal Pharmaceuticals Inc (NYSE: AMRX) announced topline data from the Phase 3 RISE-PD trial evaluating IPX-203 in patients with Parkinson's disease who have motor fluctuations. Amneal plans to submit...
Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Par...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced positive topline results from the pivotal Phase 3 RISE-PD clinical trial that evaluated the novel formulatio...
Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkins...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will host a virtual event for the investment community on Wednesday, August 25, 2021 at 4:30 p.m. ET...
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Top Estimates
Amneal (AMRX) delivered earnings and revenue surprises of 38.89% and 1.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Amneal Q2 Earnings Tops Estimates; Backs FY21 Guidance
Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q2 revenue of $535 million, an increase of 15% Y/Y, beating the consensus of $523.25 million. Sales growth was driven by Generic product launches, special...
Amneal Pharmaceuticals: Q2 Earnings Insights
Shares of Amneal Pharmaceuticals (NYSE:AMRX) moved higher by 0.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 92.31% year over year to $0....
Amneal Reports Second Quarter 2021 Financial Results
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE:AMRX) (the “Company”) announced its results today for the second quarter ended June 30, 2021. “Our strong second quarter results re...
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Receives Approval for Generic TobraDex®
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U...
Amneal to Report Second Quarter 2021 Results on August 9, 2021
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2021 financial results on Monday, August 9, 2021, prior to ...
10 Stocks Under $10 to Buy In July for the Rest of the Year
10 Stocks to watch now trading under $10 with significant upside potential The post 10 Stocks Under $10 to Buy In July for the Rest of the Year appeared first on InvestorPlace. More From InvestorPlace S...
AMRX vs. ZTS: Which Stock Should Value Investors Buy Now?
AMRX vs. ZTS: Which Stock Is the Better Value Option?
Amneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer
The FDA has accepted for review Amneal Pharmaceuticals Inc's (NYSE: AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway of the Public Health Service Act. The cover...